Ampersand Capital Partners Recognized Among GrowthCap’s Top Private Equity Firms of 2026

Boston, MA, August 27, 2026 - Ampersand Capital Partners, a healthcare and life sciences focused private equity firm with nearly 35 years of experience building market-leading companies, has been named to GrowthCap's Top Private Equity Firms of 2026, marking the third consecutive year the firm has received this recognition. The list recognizes firms that GrowthCap views as standout partners to their portfolio companies amid a private equity market it describes as more demanding than in recent years, marked by more discerning capital, shifting exit timing, and buyers scrutinizing acquisitions more closely.

Herb Hooper, Managing Partner of Ampersand, said, "Over the last several years, sector expertise and operational discipline have mattered more than ever. Our team works alongside management to build stronger, more resilient healthcare and life sciences businesses. Being named to this list for a third consecutive year is a meaningful reflection on our consistency, and we're grateful to GrowthCap for recognizing the work we do every day alongside our portfolio companies."

The recognition follows Ampersand's recent close of Ampersand 2026 Limited Partnership ("AMP-26"), the firm's twelfth primary fund since 1992. AMP-26 closed oversubscribed at its $1.5 billion hard cap in a single close less than five months after launch, with commitments from a diversified, global base of institutional investors.

GrowthCap's selections draw on more than two decades of observing the private equity industry, including conversations throughout the year with investors, founders, CEOs, and other professionals across the private capital ecosystem, alongside an ongoing review of firm activity, investments, leadership, and performance. The evaluation also incorporated nomination materials, direct firm communications, online submissions, proprietary research, and feedback from portfolio company CEOs, industry peers, and other private capital professionals.

To see the full list of honorees and learn more about the selection criteria and methodology, please visit the GrowthCap website.

Disclaimer: This award was provided by GrowthCap on August 27, 2026, and based on the time period of January 1, 2025 to June 30, 2026. Ampersand submitted a nomination to be considered for the GrowthCap Top Private Equity Firms 2026 list and, once selected by GrowthCap as an honoree, Ampersand paid a publishing and copyright fee to GrowthCap to promote this award. The data provided in this award publication is for informational purposes only and should not be construed as investment advice, endorsement, nor recommendation. GrowthCap believes the information in this publication to be accurate but does not verify its accuracy independently and does not warrant or guarantee that it is accurate or complete. GrowthCap has no obligation to provide any updates or changes to the information. No investment decisions should be made using this information.

About Ampersand Capital Partners

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with over $4 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, Amsterdam, and London, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit www.ampersandcapital.com or follow us on LinkedIn.